BioHarvest Sciences

CEO Ilan Sobel discusses today's 'in vitro' test results for Bioharvest's Olive Cell compound. "100mg of the Olive Cell compound contains as much verbascoside as 2 litres of olive oil". Watch interview: https://bit.ly/3QH15g3

CEO interview--> Ilan Sobel discusses March 31 Earnings results with Martin Gagel of Radius Research. Watch: https://lnkd.in/gYPTFDhB

"The top line really jumps off the page.." CEO Ilan Sobel discusses newly released Q4 and Full Year 2024 financials. Watch interview: https://lnkd.in/gXFgKS6s - 2024 Revenues increase 99% to $25.2 million - Q4 revenue up 62% YoY to $7.3 million - 2024 gross margins increase 1000 basis points to 55% - Total VINIA® subscribers surpassed 50,000 as of February 2025

News Release--> BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results- Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 Million. View Full Release: https://lnkd.in/gXfj2-BS

BioHarvest Sciences to Host Fourth Quarter and Full Year 2024 Earnings Call on March 31 at 4:30 p.m. Eastern Time   Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Monday, March 31, 2025, to discuss the Company’s fourth quarter and full year 2024 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information: Date: Monday, March 31, 2025 Time: 4:30 p.m. Eastern time   Webcast link: https://lnkd.in/gwAbvRK9

News Release--> BioHarvest Sciences Invited to 37th Annual Roth Investment Conference, March 16-18, 2025. Read full release: https://bit.ly/4h8ZjyV “I am pleased to announce our invitation to the 37th Annual Roth Conference, which is a high-profile opportunity to showcase BioHarvest’s transformative growth story. Following our recent Nasdaq listing and the launch of our CDMO Services Division last year, we are well positioned to execute on our mission to commercialize life-changing, plant-based compounds. These efforts have resulted in major milestones in our direct-to-consumer business, where we recently announced that VINIA had reached $50 Million in cumulative sales, and in our CDMO Services division, where we are conducting research on impactful plant-based solutions for our industry partners in the pharmaceutical, nutraceutical, cosmetics, and nutrition sectors.”--CEO Ilan Sobel #biotech #VINIA #sustainableinvesting #growthinvesting

News Release-->BioHarvest In Vitro testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells. Read full release: https://lnkd.in/gAseqwEc “Non-alcoholic fatty liver disease impacts over 100 million Americans, and as part of our mission to develop life-changing compounds from plants, we believe our Olive Cell Product will have the capacity to be a next-generation therapeutic solution for improving liver health in millions of American consumers” --- Ilan Sobel, CEO of BioHarvest.

New Interview--> CEO Ilan Sobel has a "deep-dive" conversation with Martin Gagel of Radius Research, discussing Botanical Synthesis, BioHarvest's CDMO research initiatives, and the company's expanding product pipeline. Watch full interview: https://bit.ly/4gG8qa1

New interview--> CEO Ilan Sobel discusses major VINIA milestones with Steve Darling of Proactive Investors. $50 Million in cumulative sales and 50,000+ VINIA subscribers! Watch: https://bit.ly/4k1FnAK

News Release--> BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD. "Commercial success of VINIA validates the power of BioHarvest’s patented Botanical Synthesis technology to produce valuable plant-based Compounds at industrial scale." Read Full release: https://bit.ly/42XKv2D